Trader notes, earnings previews, Confluences, weekly digests and roundups — long-form analysis grounded in ORTEX short interest, options flow and analyst data.
Trader Note — 14992 total
Lakefront Biotherapeutics NV heads into the final week of September with a sharp 10% weekly gain and a lending market that offers almost no friction for either side of the trade. The price story is straightforward.…
VGK, the Vanguard FTSE Europe ETF, enters the final week of September with one of the most striking options readings in its recent history — a put/call ratio that has collapsed from persistently defensive levels to…
Tencent Holdings enters the final week of September with a sharp single-day rally sitting awkwardly alongside a month that is still slightly in the red — the tension between a strong Tuesday and a soft broader trend is…
PETR4 is outperforming its own peer group this week — down just 4.1% while the broader crude complex takes a harder beating — and the positioning data explains why shorts have little appetite to press the trade. The…
NICE is having its best week in months — up 13% while most of its software peers head in the opposite direction, a divergence that makes the borrow market's calm reaction all the more striking. The price move has been…
BYD Company (1211) presents a clean reversal this week: short interest is rebuilding after several weeks of steady decline, even as the stock manages a modest recovery off its recent lows. The shift in short…
Airbus SE enters the final week of September with an unusual wrinkle in its otherwise quiet lending market: cost to borrow has tripled in a week even as short interest remains negligible, creating a disconnect worth…
DGE edges into the week on firmer ground, yet a yawning gap between where the stock trades and where analysts think it belongs frames the most interesting tension heading into October earnings. The price recovery is…
BP has shed 6.5% in a week, reversing most of the gain celebrated in last Tuesday's note, and the move is less a BP-specific story than a broad energy sector retreat. The peer group confirms the sector angle. EQNR fell…
FXI, the iShares China Large-Cap ETF, ends the week with bears in partial retreat — short interest has fallen from last week's highs, the borrow market has loosened further, and the ETF itself has nudged higher — yet…
INVA heads into the final week of September with a fresh analyst endorsement, a short base that has been quietly deflating, and a stock trading at a steep discount to where the Street thinks it belongs. The headline…
GOOGL closed Tuesday at $351.16, up nearly 1.8% on the week but giving back just over 1% on the day — a familiar pattern for a stock that is drifting higher on analyst optimism while the market remains reluctant to…
BDC heads into its October 29 earnings date with options traders taking the most cautious stance on the stock in months, even as short sellers quietly retreat and the broader peer group pushes ahead. The options market…
Domino's Pizza enters October's earnings window with a notable reversal in short positioning — but the stock has kept falling anyway, raising the question of what the dip-buyers are actually waiting for. The shift in…
RF has dropped 6% in a week and 8% over the past month, landing at $27.91 — and with Q3 results due October 16, the setup is drawing fresh short positioning and a notable analyst cut. The sharpest signal this week came…
Salesforce enters the final week of September with an interesting disconnect: short sellers who sprinted back in after the Q3 print are now quietly retreating, while a wave of analyst target upgrades sits well above…
Halozyme Therapeutics has had a sharply different week from the one the previous note described — the put-heavy options spike has reversed, shorts are trimming, and the stock has added 8.4% to close at $115.13. The…
VAW, the Vanguard Materials ETF, closed Tuesday at $227.66 — up nearly 2% on the day but down 5% over the past month, leaving the fund caught between a short-term bounce and a weaker medium-term trend. The most…
Arrowhead Pharmaceuticals has clawed back some ground after a brutal month, with the stock up 4.5% on Tuesday to $71.86 — a small but meaningful recovery from the 17% selloff documented last week, and the first sign…
TEVA enters the final week of September with one of the more unusual short-interest trajectories in the pharma space right now — a stock where the borrow market has done a full loop in under a month. The most striking…
